Articles related to SGLT2 INHIBITORS

A Swedish register-based cohort associated GLP-1 receptor agonist use with higher relative risk of anterior ischemic optic neuropathy. Absolute event rates were low, and findings attenuated after diabetes-severity controls.

Four major societies jointly published the first multidisciplinary guideline for cardiovascular-kidney-metabolic syndrome, introducing a standardized staging system and unified treatment framework across cardiology, nephrology, endocrinology, and primary care.

The Heart Failure Society of America released a scientific statement establishing diagnostic criteria and a treatment framework for heart failure with mildly reduced ejection fraction, a phenotypically heterogeneous group historically underrepresented in dedicated interventional trials.

Large-scale propensity-matched analysis reveals differential cardiovascular outcomes between GLP-1 receptor agonists and SGLT-2 inhibitors in routine clinical practice.

SGLT2 inhibitors result in 300 calories of daily glucose elimination through urinary excretion, making dietary carbohydrate choices directly impact therapeutic effectiveness.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.